Contrasting Radius Health (RDUS) and Its Competitors
Radius Health (NASDAQ: RDUS) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Radius Health to related businesses based on the strength of its institutional ownership, valuation, dividends, profitability, earnings, risk and analyst recommendations.
This table compares Radius Health and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Radius Health Competitors||-5,526.32%||-452.23%||-43.24%|
This is a summary of recent ratings and recommmendations for Radius Health and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Radius Health Competitors||765||3039||11202||227||2.71|
Radius Health currently has a consensus target price of $52.17, suggesting a potential upside of 60.51%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.81%. Given Radius Health’s higher probable upside, research analysts clearly believe Radius Health is more favorable than its rivals.
Insider and Institutional Ownership
50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 15.0% of Radius Health shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Radius Health and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Radius Health||$980,000.00||-$225.19 million||-6.26|
|Radius Health Competitors||$260.16 million||$66.28 million||-6.43|
Radius Health’s rivals have higher revenue and earnings than Radius Health. Radius Health is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Risk and Volatility
Radius Health has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Radius Health’s rivals have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.
Radius Health rivals beat Radius Health on 9 of the 12 factors compared.
Radius Health Company Profile
Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.